Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience
Authors' conclusion
Our data suggest that patient age appears to be the primary factor associated with the daily sublingual desmopressin dose required to achieve adequate clinical and biochemical control in patients with permanent AVP deficiency.
Study context
- Population
- Patients with permanent AVP-D (central diabetes insipidus), stable disease with good biochemical and clinical control under therapy ≥12 months, intact thirst132 screened
- Participants
- 96 patients
- Exposure
- Nasal spray vs Oral lyophilizate
- Nasal sprayn = 8
- Oral lyophilizaten = 88reference
- Outcome
- Clinical and biochemical predictors of daily desmopressin dose requirement
Methodological detailssingle-centre, tertiary center
- Single-centre
- Tertiary center
Main finding
As reported in the abstract
Predictors of sublingual desmopressin dose
Bivariate: dose correlated positively with estimated glomerular filtration rate (eGFR) (r)
r = 0.410
p < 0.001
Bivariate: dose correlated positively with weight (r)
r = 0.224
p = 0.036
Bivariate: dose correlated negatively with age (r)
r = - 0.433
p < 0.001
Multivariate (age, weight, eGFR): only age a significant predictor (β)
β = - 1.426
p = 0.044
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Disease duration by formulationSignificantly longer disease duration with nasal spray | P = 0.002 |
Original publication
Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience. Pituitary. Published 12 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →